MedPath

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study ...

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Perspective Therapeutics and PMV Pharma Provide Clinical Trial Updates

Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.
Perspective Therapeutics plans to initiate therapeutic dosing of PSV359, a FAP-α-targeted radiopharmaceutical, with potential study enrollment around mid-2025.

Rusfertide Achieves Primary Endpoint in Phase 3 VERIFY Trial for Polycythemia Vera

Rusfertide significantly reduced the need for phlebotomies in polycythemia vera (PV) patients, with 77% achieving clinical response compared to 33% on placebo.
The VERIFY trial met all key secondary endpoints, including hematocrit control and improved patient-reported outcomes, demonstrating comprehensive efficacy.

Humacyte's ATEV Shows Promise in Phase 3 AV Access Trial for ESRD Patients

Humacyte's acellular tissue engineered vessel (ATEV) was evaluated against autologous AV fistulas in end-stage renal disease (ESRD) patients requiring hemodialysis access.
The Phase 3 trial assessed the efficacy and safety of ATEV compared to the current standard of care, autologous AV fistulas.

Humacyte Presents Positive Phase 3 Data for Tissue-Engineered Vessel in Hemodialysis Access

Humacyte presented Phase 3 clinical trial results of its acellular tissue engineered vessel (ATEV) compared to autologous AV fistulas for hemodialysis access in end-stage renal disease patients.
The study evaluated the efficacy and safety of Humacyte's ATEV in vascular access for patients undergoing hemodialysis.

Reviva Pharma's Brilaroxazine Shows Positive Speech Latency Data in Phase 3 Schizophrenia Trial

Reviva Pharmaceuticals will present positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial at the CNS Summit 2024.
The study, titled 'Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine', highlights enhanced treatment effects.

GlycoMimetics' Uproleselan Shows Promise in Acute Myeloid Leukemia Trials

GlycoMimetics will present Phase 3 trial data on uproleselan plus chemotherapy in relapsed/refractory AML at the ASH Annual Meeting.
Updated Phase 1 results of uproleselan with azacitidine and venetoclax in treatment-naive AML will also be presented.

Suven Life Sciences' Ropanicant Shows Positive Phase 2a Results for Major Depressive Disorder

Suven Life Sciences announced positive results from its Phase 2a proof-of-concept study of Ropanicant (SUVN-911) in patients with moderate to severe Major Depressive Disorder (MDD).
Ropanicant, an α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, demonstrated promising safety and efficacy outcomes in the open-label Phase 2a study.

Trevi Therapeutics Announces Clinical Trial Progress for Haduvio in Chronic Cough

Trevi Therapeutics' Phase 2b CORAL trial for chronic cough in IPF reaches 50% enrollment; sample size re-estimation results are expected in December 2024.
Dosing is complete in the Human Abuse Potential (HAP) study for Haduvio, with topline results also anticipated in December 2024.

Rhenium-186 Obisbemeda Shows Promise in Recurrent Glioblastoma Trial

Plus Therapeutics' ReSPECT-GBM Phase 1/2 trial update reveals Rhenium-186 Obisbemeda's favorable safety profile and potential efficacy in recurrent glioblastoma treatment.
The trial achieved a mean Phase 2 absorbed dose of 300 Gy, with 89% of patients exceeding the 100 Gy minimal dose threshold, indicating effective drug delivery.

PDS Biotech Presents Promising VERSATILE-002 Data for HPV16-Positive Head and Neck Cancer

PDS Biotech will present updated data from the VERSATILE-002 trial at the ESMO Congress 2024 in Barcelona, Spain.
The trial evaluates Versamune® HPV (PDS0101) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment.

Reference News

[1]
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study ...
biospace.com · Nov 5, 2024

Protagonist Therapeutics to present final Phase 2 REVIVE study data on rusfertide for polycythemia vera at the 66th ASH ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy